4 results
8-K
EX-99.1
CGTX
Cognition Therapeutics, Inc.
4 Jan 24
Other Events
4:21pm
by third parties. Forward-looking Statements
3 Our Mission: Develop oral therapies to protect neurons and restore normal cellular damage responses
8-K
EX-99.1
CGTX
Cognition Therapeutics, Inc.
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
dementias that affect more than 55 million people worldwide. It gives us the opportunity to reflect and recommit to our mission to bring effective treatment
8-K
EX-99.1
CGTX
Cognition Therapeutics, Inc.
9 Aug 22
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
7:15am
. With these significant developments and promising signals, we believe we are well equipped to further our mission to bring new therapies to the millions
- Prev
- 1
- Next